Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques | Zendy

Timothy N. Hoang | Zendy; María Pino | Zendy; Arun K. Boddapati | Zendy; Elise G. Viox | Zendy; Carly E. Starke | Zendy; Amit A. Upadhyay | Zendy; Sanjeev Gumber | Zendy; Michael Nekorchuk | Zendy; Kathleen BusmanSahay | Zendy; Zachary Strongin | Zendy; Justin Harper | Zendy; Gregory K. Tharp | Zendy; Kathryn L. Pellegrini | Zendy; Shan G. M. Kirejczyk | Zendy; Keivan Zandi | Zendy; Sijia Tao | Zendy; Tristan R. Horton | Zendy; Elizabeth Beagle | Zendy; Ernestine Mahar | Zendy; Michelle Y. Lee | Zendy; Joyce K. Cohen | Zendy; Sherrie Jean | Zendy; Jennifer Wood | Zendy; Fawn ConnorStroud | Zendy; Rachelle L. Stammen | Zendy; Olivia M. Delmas | Zendy; Shelly Wang | Zendy; Kimberly A. Cooney | Zendy; Michael N. Sayegh | Zendy; Lanfang Wang | Zendy; Peter Filev | Zendy; Daniela Weiskopf | Zendy; Guido Silvestri | Zendy; Jesse J. Waggoner | Zendy; Anne Piantadosi | Zendy; Sudhir Pai Kasturi | Zendy; Hilmi Al-Shakhshir | Zendy; Susan Pereira Ribeiro | Zendy; RafickPierre Sékaly | Zendy; Rebecca D. Levit | Zendy; Jacob D. Estes | Zendy; Thomas H. Vanderford | Zendy; Raymond F. Schinazi | Zendy; Steven E. Bosinger | Zendy; Mirko Paiardini | Zendy

Open Access

Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

Author(s) -

Timothy N. Hoang,

María Pino,

Arun K. Boddapati,

Elise G. Viox,

Carly E. Starke,

Amit A. Upadhyay,

Sanjeev Gumber,

Michael Nekorchuk,

Kathleen BusmanSahay,

Zachary Strongin,

Justin Harper,

Gregory K. Tharp,

Kathryn L. Pellegrini,

Shan G. M. Kirejczyk,

Keivan Zandi,

Sijia Tao,

Tristan R. Horton,

Elizabeth Beagle,

Ernestine Mahar,

Michelle Y. Lee,

Joyce K. Cohen,

Sherrie Jean,

Jennifer Wood,

Fawn ConnorStroud,

Rachelle L. Stammen,

Olivia M. Delmas,

Shelly Wang,

Kimberly A. Cooney,

Michael N. Sayegh,

Lanfang Wang,

Peter Filev,

Daniela Weiskopf,

Guido Silvestri,

Jesse J. Waggoner,

Anne Piantadosi,

Sudhir Pai Kasturi,

Hilmi Al-Shakhshir,

Susan Pereira Ribeiro,

RafickPierre Sékaly,

Rebecca D. Levit,

Jacob D. Estes,

Thomas H. Vanderford,

Raymond F. Schinazi,

Steven E. Bosinger,

Mirko Paiardini

Publication year - 2020

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2020.11.007

Subject(s) - biology , inflammation , immunology , macrophage , covid-19 , virology , pandemic , pathology , disease , genetics , infectious disease (medical specialty) , medicine , outbreak , in vitro

SARS-CoV-2-induced hypercytokinemia and inflammation are critically associated with COVID-19 severity. Baricitinib, a clinically approved JAK1/JAK2 inhibitor, is currently being investigated in COVID-19 clinical trials. Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages, and tissues was not reduced with baricitinib. Type I interferon (IFN) antiviral responses and SARS-CoV-2-specific T cell responses remained similar between the two groups. Animals treated with baricitinib showed reduced inflammation, decreased lung infiltration of inflammatory cells, reduced NETosis activity, and more limited lung pathology. Importantly, baricitinib-treated animals had a rapid and remarkably potent suppression of lung macrophage production of cytokines and chemokines responsible for inflammation and neutrophil recruitment. These data support a beneficial role for, and elucidate the immunological mechanisms underlying, the use of baricitinib as a frontline treatment for inflammation induced by SARS-CoV-2 infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research